Corvus Pharmaceuticals (CRVS) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

CRVS Stock Forecast


Corvus Pharmaceuticals stock forecast is as follows: an average price target of $9.50 (represents a 5.32% upside from CRVS’s last price of $9.02) and a rating consensus of 'Buy', based on 1 wall street analysts offering a 1-year stock forecast.

CRVS Price Target


The average price target for Corvus Pharmaceuticals (CRVS) is $9.50 based on 1-year price targets from 1 Wall Street analysts in the past 3 months, with a price target range of $12.00 to $7.00. This represents a potential 5.32% upside from CRVS's last price of $9.02.

CRVS Analyst Ratings


Buy

According to 1 Wall Street analysts, Corvus Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for CRVS stock is 0 'Strong Buy' (0.00%), 1 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Corvus Pharmaceuticals Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 22, 2024Graig SuvannavejhMizuho Securities$12.00$7.5658.73%33.04%
Aug 18, 2023Jeff JonesOppenheimer$7.00$2.19219.65%-22.39%
Row per page
Go to

The latest Corvus Pharmaceuticals stock forecast, released on Oct 22, 2024 by Graig Suvannavejh from Mizuho Securities, set a price target of $12.00, which represents a 58.73% increase from the stock price at the time of the forecast ($7.56), and a 33.04% increase from CRVS last price ($9.02).

Corvus Pharmaceuticals Price Target by Period


1M3M12M
# Anlaysts111
Avg Price Target$12.00$12.00$12.00
Last Closing Price$9.02$9.02$9.02
Upside/Downside33.04%33.04%33.04%

In the current month, the average price target of Corvus Pharmaceuticals stock is $12.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 33.04% increase as opposed to Corvus Pharmaceuticals's last price of $9.02. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 07, 2024OppenheimerOutperformOutperformHold
Aug 18, 2023Oppenheimer-OutperformInitialise
Row per page
Go to

Corvus Pharmaceuticals's last stock rating was published by Oppenheimer on May 07, 2024. The company gave CRVS a "Outperform" rating, the same as its previous rate.

Corvus Pharmaceuticals Financial Forecast


Corvus Pharmaceuticals Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
Revenue-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
# Analysts-------
Surprise %-------

Corvus Pharmaceuticals's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. CRVS's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).

Corvus Pharmaceuticals EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EBITDA-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

undefined analysts predict CRVS's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Corvus Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.

Corvus Pharmaceuticals Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
Net Income-------
Avg Forecast$-8.96M$-8.96M$-8.36M$-8.36M$-7.02M$-6.57M$-6.87M
High Forecast$-8.96M$-8.96M$-8.36M$-8.36M$-7.02M$-5.97M$-6.87M
Low Forecast$-8.96M$-8.96M$-8.36M$-8.36M$-7.02M$-6.57M$-6.87M
Surprise %-------

Corvus Pharmaceuticals's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CRVS's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Corvus Pharmaceuticals SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
SG&A-------
Avg Forecast-------
High Forecast-------
Low Forecast-------
Surprise %-------

Corvus Pharmaceuticals's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to CRVS last annual SG&A of $NaN (undefined).

Corvus Pharmaceuticals EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24
# Analysts-------
EPS-------
Avg Forecast$-0.15$-0.15$-0.14$-0.14$-0.12$-0.11$-0.12
High Forecast$-0.15$-0.15$-0.14$-0.14$-0.12$-0.10$-0.12
Low Forecast$-0.15$-0.15$-0.14$-0.14$-0.12$-0.11$-0.12
Surprise %-------

According to undefined Wall Street analysts, Corvus Pharmaceuticals's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CRVS previous annual EPS of $NaN (undefined).

Corvus Pharmaceuticals Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
XFORX4 Pharmaceuticals$0.53$3.67592.45%Buy
INZYInozyme Pharma$4.42$14.67231.90%Buy
PDSBPDS Bio$3.23$9.00178.64%Buy
DAWNDay One Biopharmaceuticals$14.81$38.80161.99%Buy
ABOSAcumen Pharmaceuticals$2.95$7.00137.29%Buy
TERNTerns Pharmaceuticals$7.10$14.25100.70%Buy
MREOMereo BioPharma Group$4.01$6.7568.33%Buy
CRVSCorvus Pharmaceuticals$9.02$9.505.32%Buy
HOOKHOOKIPA Pharma$3.76$3.00-20.21%Buy

CRVS Forecast FAQ


Yes, according to 1 Wall Street analysts, Corvus Pharmaceuticals (CRVS) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 100.00% of CRVS's total ratings.

Corvus Pharmaceuticals (CRVS) average price target is $9.5 with a range of $7 to $12, implying a 5.32% from its last price of $9.02. The data is based on 1 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

According to Wall Street analysts' prediction for CRVS stock, the company can go up by 5.32% (from the last price of $9.02 to the average price target of $9.5), up by 33.04% based on the highest stock price target, and down by -22.39% based on the lowest stock price target.

CRVS's average twelve months analyst stock price target of $9.5 does not support the claim that Corvus Pharmaceuticals can reach $14 in the near future.

1 Wall Street analyst forecast a $12 price target for Corvus Pharmaceuticals (CRVS) this month, up 33.04% from its last price of $9.02. Compared to the last 3 and 12 months, the average price target increased by 33.04% and increased by 33.04%, respectively.

Corvus Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-20.451M (high $-19.854M, low $-20.451M), average SG&A $0 (high $0, low $0), and average EPS is $-0.342 (high $-0.333, low $-0.342). CRVS's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-34.632M (high $-34.632M, low $-34.632M), average SG&A $0 (high $0, low $0), and average EPS is $-0.58 (high $-0.58, low $-0.58).